Clinical Trial · NCT06881823

NeoPSMA: A Phase I/II, Open-label, Multi-center Study of Neoadjuvant Treatment With [177Lu]Lu-PSMA-R2 (AAA602) and [225Ac]Ac-PSMA-R2 (AAA802) in Adults With Prostate-specific Membrane Antigen (PSMA) Positive High-risk Localized Prostate Cancer (HRLPC) Prior to Radical Prostatectomy and Pelvic Lymph Node Dissection

Overview

The purpose of this trial is to learn more about the effects of AAA602 and AAA802 in men with prostate-specific membrane antigen (PSMA) positive high-risk localized prostate cancer (HRLPC) before surgery to remove the prostate and lymph nodes present in the pelvis area. Lymph nodes are small structures near the prostate that help fight infections. These lymph nodes are removed during surgery because they are a site the disease can spread to.

Sponsor

Novartis

Phase

Phase 1/2

Contacts

Novartis Pharmaceuticals

novartis.email@novartis.com

1-888-669-6682

ClinicalTrials.gov

NCT06881823

Drug / Compound

[177Lu]Lu-PSMA-R2 (AAA602)

Isotope(s):
Target(s):
  • PSMA

[225Ac]Ac-PSMA-R2 (AAA802)

Isotope(s):
Target(s):